BD和Ypsomed合作开发高粘度生物制品的自注射系统-动脉网

BD and Ypsomed Collaborate to Advance Self-Injection Systems for High Viscosity Biologics

碧迪医疗等信源发布 2024-10-23 19:00



可切换为仅中文







Le Pont-de-Claix, France & Burgdorf, Switzerland (October 23, 2024) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a strategic collaboration with Ypsomed, a leading developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs.

Le Pont de Claix，France&Burgdorf，Switzerland（2024年10月23日）–全球领先的医疗技术公司BD（Becton，Dickinson and Company）（纽约证券交易所：BDX）宣布与领先的注射系统开发商Ypsomed进行战略合作，以推进高粘度生物药物的自注射解决方案。

In a joint project, Ypsomed and BD have pre-assessed and streamlined integration of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with Ypsomed’s YpsoMate® 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format..

在一个联合项目中，Ypsomed和BD已经预先评估并简化了BD Neopak™XtraFlow™玻璃预填充注射器与Ypsomed的YpsoMate®2.25自动注射器平台的集成，通过以自动注射器的形式提供更高粘度（>15cP）的生物药物来解决当前的局限性。。

Designed to flow beyond limits

设计用于流量超出限制

The BD Neopak™ XtraFlow™ Glass Prefillable Syringe is BD’s latest portfolio addition, featuring a shorter, 8-millimeter needle length, and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today’s limits versus a standard half-inch needle1,2* This solution is a part of the BD Neopak™ Glass Prefillable Syringe Platform, which is designed to address key development needs for biologic drugs..

BD Neopak™XtraFlow™玻璃预填充注射器是BD最新的产品组合，具有更短的8毫米针头长度和更薄的壁套管，可优化高粘度药物的皮下输送。这一改进使制药开发人员能够打破设计障碍，提高流量和可用性，超越当今的限制，而不是标准的半英寸针头1,2*该解决方案是BD Neopak™玻璃预填充注射器平台的一部分，该平台旨在解决生物药物的关键开发需求。。

To support this innovation, Ypsomed is expanding its YpsoMate® 2.25 two-step autoinjector platform to accommodate the new syringe format. This includes adapting parts of the autoinjector for the shorter needle, qualifying tooling and assembly, and performing extensive technical testing to ensure reliability.

为了支持这项创新，Ypsomed正在扩展其YpsoMate®2.25两步自动注射器平台，以适应新的注射器格式。这包括调整自动注射器的部件以适应较短的针头，鉴定工具和组件，并进行广泛的技术测试以确保可靠性。

The YpsoMate autoinjector device is handled in two steps: simply remove the cap and push on skin, designed so that people with impaired grip or vision can administer their medication easily and safely..

YpsoMate自动注射器分两步操作：只需取下盖子并按压皮肤，其设计使握力或视力受损的人可以轻松安全地服用药物。。

Supporting our pharmaceutical partners to de-risk and accelerate combination product development

支持我们的制药合作伙伴降低风险并加速组合产品开发

“We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with the YpsoMate® 2.25 autoinjector,” said Ulrike Bauer, Chief Business Officer of Ypsomed Delivery Systems. “This collaboration underscores our commitment to enhancing patient care through innovative drug delivery solutions.”.

Ypsomed Delivery Systems首席商务官乌尔里克·鲍尔（Ulrike Bauer）表示：“我们很高兴欢迎第一批制药客户体验到BD Neopak™XtraFlow™玻璃预充注射器和Ypsomet®2.25自动注射器的优点。”。“这种合作强调了我们通过创新的药物输送解决方案加强患者护理的承诺。”。

“Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.” .

BD pharmaceutical Systems全球总裁Patrick Jeukenne表示：“跨供应商合作在当今的制药生态系统中至关重要。”。“这些伙伴关系可以帮助推动创新，确保系统按设计和生命周期工作，使我们的制药合作伙伴能够更快地为患者提供挽救生命的疗法。”。

BD and Ypsomed are key leaders in drug delivery, enabling the administration of chronic condition therapeutics such as GLP-1s, antibodies, and other next generation formulations. Combining BD’s robust syringe platform technology with Ypsomed’s leading autoinjector platform, this collaboration leverages shared expertise to deliver reliable device systems..

BD和Ypsomed是药物输送的关键领导者，能够管理慢性病治疗药物，如GLP-1，抗体和其他下一代制剂。。。

1. Injection time and ejection force calculation [internal study], Le Pont-de-Claix, France; Becton, Dickinson and Company, 2021

1、注射时间和弹射力计算[内部研究]，Le Pont de Claix，法国；Becton，Dickinson and Company，2021年

2. Pager et al. (2020), “User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with staked 8 mm ultra-thin wall needle”, Expert Opinion on Drug Delivery, https://doi.org/10.1080/17425247.2020.1796630.

2.Pager等人（2020年），“新型8毫米超薄壁针头预填充注射器增强了手动注射2毫升粘性溶液的用户体验”，药物输送专家意见，https://doi.org/10.1080/17425247.2020.1796630.

*When compared to 12.7 mm special thin wall needle

*与12.7毫米特殊薄壁针相比

YpsoMate is a registered trademark of Ypsomed AG.

YpsoMate是Ypsomed AG的注册商标。

About BD

关于BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

BD是世界上最大的全球医疗技术公司之一，正在通过改进医疗发现、诊断和护理服务来推动世界健康。该公司通过开发创新技术、服务和解决方案来支持医疗保健前线的英雄，这些技术、服务和解决方案有助于推进患者的临床治疗和医疗保健提供者的临床过程。

BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

BD及其70000多名员工充满热情并致力于帮助提高临床医生护理过程的安全性和效率，使实验室科学家能够准确检测疾病，并提高研究人员开发下一代诊断和治疗方法的能力。

BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

BD在几乎每个国家都有业务，并与世界各地的组织合作，以解决一些最具挑战性的全球健康问题。通过与客户密切合作，BD可以帮助提高成果，降低成本，提高效率，提高安全性并扩大医疗保健的范围。

For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. .

有关BD的更多信息，请访问BD.com或通过LinkedIn与我们联系，网址为www.LinkedIn.com/company/bd1/，X（以前的Twitter）@BDandCo或Instagram@becton\u dickinson。。

Contacts:

联系人：

Media:

媒体：

Fallon McLoughlin

法伦·麦克洛林

Director, Public Relations

公共关系总监

201.258.0361

fallon.mcloughlin@bd.com

Investors: